Crucell is a fully-integrated biopharmaceutical company. We focus on developing, producing and marketing products that combat infectious diseases.
Mission: Combating infectious diseases
Crucell’s mission is to develop, produce and market vaccines and antibodies that prevent or treat infectious diseases.
Crucell Sweden AB is a Swedish registered company with in-house development and manufacturing capabilities, marketing our specialist vaccines internationally. A complete vaccine portfolio sourced from global vaccine companies is marketed in the Nordic region by our distribution division based in Stockholm.
Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. Crucell focuses on the reasearch & development, production and marketing of vaccines and antibodies against infectious disease worldwide. Currently we are combating twelve major infectious diseases with its range of marketed vaccines in the paediatric, travel and endemic and respiratory fields.
Headquartered in Leiden, The Netherlands, Crucell currently employs more than 1200 people and has subsidiaries in Switzerland, Spain, Sweden, Italy, Korea the United Kingdom and the United States. Crucell N.V. is listed on Euronext and NASDAQ (CRXL) and the SWX Swiss Exchange (CRX). At Crucell, we’re bringing innovation to global health.
Crucell has a broad development pipeline, including vaccines and antibody products. Several Crucell products are based on our unique PER.C6® production technology. Crucell licenses this and other cutting edge technologies to the biopharmaceutical industry. Important partners and licensees are Johnson & Johnson, DSM Biologics, Novartis, sanofi aventis, MedImmune, GSK, CSL, Merck and Wyeth.
Berna Biotech, SBL Vaccines, Berna Products Corporation and Green Cross Vaccine Corporation are trade names / marks formerly used for distribution of Crucell products.